8-K current report · filed Jul 31, 2026

Neurocrine Biosciences Inc (NBIX) 8-K Current Report: July 31, 2026

Item EX-99.1NBIX overview

Short answer

Neurocrine Biosciences Inc (NBIX) filed an 8-K current report with the SEC on July 31, 2026 reporting Item EX-99.1 (Exhibit EX-99.1). Soleno acquisition closed May 18, 2026 at $53.00 per share, adding VYKAT XR for Prader-Willi syndrome.

Neurocrine Biosciences Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item EX-99.1 · Exhibit EX-99.1

  • Soleno acquisition closed May 18, 2026 at $53.00 per share, adding VYKAT XR for Prader-Willi syndrome
  • Pro forma revenue $3,050.9M in 2025, including $190.4M from Soleno
  • Pro forma net income $324.5M in 2025, with diluted EPS $3.17 after acquisition-related amortization
  • VYKAT XR valued at $2,237.8M, creating $139.9M of 2025 pro forma amortization expense
  • Acquisition funded through a $1.0B revolving facility, with $600.0M drawn at 4.896% and fully repaid by June 30, 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Neurocrine Biosciences Inc 8-K filings

Get the next NBIX 8-K as it lands

Follow NBIX for push alerts, or ask the research agent what this filing means.